Here are the Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.
Real world evaluation of the effects of marijuana, real world evaluation of wearable fitness, real world evaluation of the effects of environmental change, real world evaluation of the effects of tirzepatide dosing, real world evaluation of the effects of music on the brain, real world map, real world evaluation of the effects of tirzepatide side, real world evaluation of the effects of tirzepatide compounding, real world evaluation of medication, real world evaluation of the effects of social media.
Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus
Aims: Tirzepatide is a first-in-class combination glucose-dependent insulinotropic polypeptide (GIP) receptor agonist and glucagon-like peptide 1 receptor agonist (GLP1-RA) approved for treatment of adults with type 2 diabetes mellitus (T2DM) and chronic weight management. The aim of this analysis was to assess the real-world efficacy of tirzepatide in patients with T2DM.
Methods: This retrospective observational study evaluated patients with T2DM from a large urban academic medical centre who received at least 3 months of continuous tirzepatide treatment. The primary outcome was change in A1C from following tirzepatide treatment. Secondary outcomes included change in body weight and body mass index (BMI) after tirzepatide was initiated.
Results: A total of 1896 patient charts were reviewed, and 612 patients were evaluated for the primary outcome. Over a median time period of 10.4 months, treatment with tirzepatide resulted in a mean A1C reduction of 1.02 ± 1.48% (p < 0.001). A total of 570 patients were evaluated for the secondary outcomes. Tirzepatide was associated with a mean reduction in body weight of 7.3 ± 9.3 kg (p < 0.001) and a mean reduction in BMI of 2.5 kg/m2. Greater A1C lowering and weight loss was observed in patients without prior GLP1-RA treatment compared to those switched to tirzepatide from GLP1-RA. Conclusions: In a real-world population of US patients with T2DM, tirzepatide was associated with clinically and statistically significant reductions in A1C and body weight. Greater reductions in both A1C and body weight were observed among patients who were GLP1-RA naïve compared to patients switched from GLP1-RA to tirzepatide. © 2024 The Author(s). Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Authors : Kelly M.S.; Scopelliti E.M.; Goodson K.E.; Lo C.M.A.; Nguyen H.X.; Simon B.
Source : John Wiley and Sons Inc
Article Information
| Year | 2024 |
| Type | Article |
| DOI | 10.1111/dom.15934 |
| ISSN | 14628902 |
| Volume | 26 |
You can download the article here
If You have any problem, contact us here